Search

Efficacy assessments using a combination of ibrutinib and lenalidomide necessitate the development of an analytical method for determination of both drugs in plasma with precision. A high performance liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was developed for the simultaneous determination of lenalidomide, ibrutinib, and its active metabolite PCI45227 in rat plasma. Extraction of lenalidomide, ibrutinib, PCI45227 and tolbutamide (internal standard; IS) from 50 μl rat plasma was carried out by liquid–liquid extraction with ethyl acetate:dichloromethane (90:10) ratio. Chromatographic separation of analytes was performed on YMC pack ODS AM (150 mm × 4.6 mm, 5 μm) column under gradient conditions with acetonitrile:0.1% formic acid buffer as the mobile phases at a flow rate of 1 ml/min. Precursor ion and product ion transition for analytes and IS were monitored on a triple quadrupole mass spectrometer, operated in the selective reaction monitoring with positive ionization mode. Method was validated over a concentration range of 0.72–183.20 ng/ml for ibrutinib, 0.76–194.33 ng/ml for PCI-45227 and 1.87–479.16 ng/ml for lenalidomide. Mean extraction recovery for ibrutinib, PCI-45227, lenalidomide and IS of 75.2%, 84.5%, 97.3% and 92.3% were consistent across low, medium, and high QC levels. Precision and accuracy at low, medium and high quality control levels were less than 15% across analytes. Bench top, wet, freeze–thaw and long term stability was evaluated for all the analytes. The analytical method was applied to support a pharmacokinetic study of simultaneous estimation of lenalidomide, ibrutinib, and its active metabolite PCI-45227 in Wistar rat. Assay reproducibility was demonstrated by re-analysis of 18 incurred samples. [ABSTRACT FROM AUTHOR]

Highlights: [•] Highly selective method for the determination of ruxolitinib and nilotinib in plasma. [•] This is the first LC–MS/MS-based method for simultaneous determination of ruxolitinib and nilotinib in plasma. [•] Plasma sample clean-up involves a simple protein precipitation procedures. [•] The developed LC–MS/MS based method was applied successfully for pharmacokinetic study. [Copyright &y& Elsevier]

Highlights: [•] Highly selective method for the determination of idelalisib, fludarabine and lenalidomide in plasma. [•] This is the first LC-MS/MS-based method for simultaneous determination of idelalisib, fludarabine and lenalidomide in plasma. [•] Plasma sample clean-up involves a simple liquid–liquid extraction procedures. [•] The developed LC-MS/MS-based method was applied successfully for pharmacokinetic study. [ABSTRACT FROM AUTHOR]